Compare OFIX & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OFIX | STRO |
|---|---|---|
| Founded | 1987 | 2003 |
| Country | United States | United States |
| Employees | N/A | 133 |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 473.3M | 381.1M |
| IPO Year | 1998 | N/A |
| Metric | OFIX | STRO |
|---|---|---|
| Price | $11.32 | $22.94 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 9 |
| Target Price | $17.25 | ★ $31.33 |
| AVG Volume (30 Days) | 383.7K | ★ 441.4K |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 29.39 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $822,312,000.00 | N/A |
| Revenue This Year | $6.13 | N/A |
| Revenue Next Year | $6.22 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 2.85 | N/A |
| 52 Week Low | $8.85 | $0.72 |
| 52 Week High | $16.99 | $43.85 |
| Indicator | OFIX | STRO |
|---|---|---|
| Relative Strength Index (RSI) | 53.87 | 34.27 |
| Support Level | $11.11 | $19.11 |
| Resistance Level | $12.40 | $27.96 |
| Average True Range (ATR) | 0.50 | 2.14 |
| MACD | -0.03 | -0.55 |
| Stochastic Oscillator | 34.88 | 10.83 |
Orthofix Medical Inc. is a medical device company delivering orthopedic and spine solutions to healthcare providers. The company has two reportable segments: Global Spine and Global Limb Reconstruction. The Global Spine segment offers bone growth therapies, spinal implants, biologics, and enabling technologies used in spinal procedures. The Global Limb Reconstruction segment provides products and solutions for limb deformity correction, limb lengthening, fracture management, and limb preservation, supported by digital technologies. It generates the majority of its revenue from the Global Spine segment.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.